NanoXplore Announces Conversion of Outstanding Debentures

NanoXplore Inc. (" NanoXplore " or the " Corporation ") (TSX-V: GRA and OTCQX: NNXPF) is pleased to announce that on December 8, 2020, it received a notice of conversion from BDC Capital Inc. (" BDC Capital ") of its 10,000 convertible unsecured subordinated debentures of the Corporation bearing interest at 8% per annum, for an aggregate principal amount of $10,000,000 (the " Debentures ").

The Debentures were converted into common shares of the Corporation at a price of $1.84 per common share, resulting in the issuance of 5,434,782 common shares of the Corporation. Following the conversion, BDC Capital now owns 10,819,397 common shares of NanoXplore, representing 7.41% of its total outstanding shares.

Soroush Nazarpour, President and CEO of NanoXplore, commented:

" We are pleased to have received this notice of conversion of Debentures from BDC Capital in advance of their original maturity date in December 2023. This conversion significantly reduces the Corporation's debt obligations and affords additional flexibility and runway to accelerate revenue growth as we continue our path toward profitability. "

Jérôme Nycz, Executive Vice President, BDC Capital, commented:

" Graphene is one of the most promising nanomaterials offering a solution for companies across multiple industries seeking to meet their sustainability goals. We are happy to accelerate our support for NanoXplore's growth prospects by converting our debentures as management continues to deliver on their milestones accreting significant value in the process."

About NanoXplore Inc.

NanoXplore is a graphene company, a manufacturer and supplier of high-volume graphene powder for use in industrial markets. The company provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors. NanoXplore is headquartered in Montreal, Quebec with manufacturing facilities across Canada, the United States and Europe.

About BDC Capital

BDC Capital is the investment arm of BDC, Canada's bank for entrepreneurs. With over $3 billion under management, BDC Capital serves as a strategic partner to the country's most innovative firms. It offers businesses a full spectrum of capital, from seed investments to growth equity, supporting Canadian entrepreneurs who have the ambition to stand out on the world stage. Visit bdc.ca/capital .

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, please contact:

Soroush Nazarpour
President & CEO
NanoXplore Inc.
+1 (514) 935-1677
info@NanoXplore.ca


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Longeveron Granted Small or Medium-sized Enterprise  Status by the European Medicines Agency

Longeveron Granted Small or Medium-sized Enterprise Status by the European Medicines Agency

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines... Keep Reading...
Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Contract manufacturing services as a new business line has the potential to generate approximately $4-5 million in annual revenues First manufacturing services contract signed with Secretome Therapeutics Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company... Keep Reading...
Immatics Announces First Quarter 2024 Financial Results and Business Update

Immatics Announces First Quarter 2024 Financial Results and Business Update

Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, including tumor... Keep Reading...
Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce an innovative research initiative to be undertaken with The Giacomantonio Immuno-Oncology Research Group (the "Research Group"). This study aims to evaluate the efficacy of Sona's Targeted... Keep Reading...
Why Invest in Nanotech Stocks?

Why Invest in Nanotech Stocks?

The nanotechnology market is experiencing a promising stage of growth, making it an attractive space for investors.From nanotech-based solar panels that increase energy efficiency to pharmaceutical products that make use of nanotech in drug-delivery systems, nanotechnology has far-reaching... Keep Reading...

SILO Pharma Inc

SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. Keep Reading...

Interactive Chart

Latest Press Releases

Related News